Filing Flows › BioMarin Pharmaceutical (BMRN) › Royalty and other revenues revenue
BioMarin Pharmaceutical (BMRN) Royalty and other revenues revenue by quarter
BioMarin Pharmaceutical's Royalty and other revenues revenue was $11.6M in Q3 2026 (third quarter 2026), +118% from Q2 2026. Over the last 7 quarters it ranged from $5.3M (Q2 2026) to $15.3M (Q3 2025).
| Quarter | Royalty and other revenues revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $11.6M | +118% | -25% |
| Q2 2026 | $5.3M | -13% | -57% |
| Q1 2026 | $6.1M | -60% | -42% |
| Q4 2025 | $15.2M | -0.5% | — |
| Q3 2025 | $15.3M | +23% | — |
| Q2 2025 | $12.4M | +18% | — |
| Q1 2025 | $10.5M | — | — |
Q3 2026 at a glance
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
Questions
What is BioMarin Pharmaceutical's Royalty and other revenues revenue?
BioMarin Pharmaceutical's Royalty and other revenues revenue was $11.6M in Q3 2026 (third quarter 2026), +118% from Q2 2026.
How has BioMarin Pharmaceutical's Royalty and other revenues revenue changed?
Over the last 7 quarters it ranged from $5.3M (Q2 2026) to $15.3M (Q3 2025).
Q3 2026 results → · How BioMarin Pharmaceutical makes money →